The application, which includes a request for priority review, is specifically for lovotibeglogene autotemcel (lovo-cel) to treat SCD patients aged 12 years and older who have a history of painful complications associated with the disease.
Affecting approximately 100,000 people in the US, SCD is a life-long, incurable genetic disease causing red blood cells to take a distinct crescent shape, which can block blood vessels and affect the way oxygen is carried around the body.
